Significant progress made over the last few decades in the management and treatment of many neurodegenerative diseases. However, successful translation of effective therapeutic compounds from animal models to humans has been disappointing. This chapter provides an overview of the current models of drug development and clinical trial design along with a summary of the advantages and limitations of each model. The chapter also discusses the challenges of performing clinical trials in neurodegenerative disorders, including the selection of appropriate biomarkers of disease activity and the appropriate definition of meaningful clinical outcomes, and identifies promising new approaches towards the development of efficacious disease modifying therapeutics.
|Title of host publication||Neurodegenerative Disorders|
|Editors||Orla Hardiman, P. Colin Doherty, Marwa Elamin, Peter Bede|
|Place of Publication||Cham|
|Publisher||Springer International Publishing|
|Number of pages||15|
|Publication status||Published - 27 Feb 2016|